Balance Therapeutics

Our Programs

img-pipeline.png

We are developing medicines that can improve the lives of people with debiliating, neurological conditions. Our lead product candidate BTD-001, a small molecule GABA antagonist, is in development for the treatment of excessive daytime sleepiness in Idiopathic Hypersomnia and Narcolepsy Type 2 and for cognitive impairment in Down syndrome. We are also developing next generation products that share the pharmacological features of BTD-001 and may offer clinical advantages.


Pipeline

Program/Product
Preclinical
Phase 1
Phase 2
Phase 3

Rare Sleep Disorders

Phase 2
Phase 2

Cognitive Impairment

Phase 1
Rare Sleep Disorders
(Next Gen Analogs)
Preclinical